The pending combination with Kimberly-Clark is the single biggest event hanging over Kenvue this quarter, and it sits in front of an otherwise quiet operating story. On November 2, 2025 the board approved a definitive merger agreement. Under the terms, Kenvue shareholders receive 0.14625 shares of Kimberly-Clark common stock plus $3.50 in cash for each share held. The transaction is expected to close in the fourth quarter of 2026 subject to customary regulatory clearances. The Kenvue side has already cleared the U.S. antitrust waiting period and obtained shareholder approval in late January, leaving the remaining work concentrated in foreign jurisdictions. The mechanical implication of the deal is a current share-price ceiling roughly equal to the cash plus the implied value of the K-C stock component, and the equity has been trading in a narrow band as the market waits for that closing catalyst. Shares of Kenvue last changed hands at $18.75, near the upper end of a fifty-two-week range. The market capitalization sits near $36.0B and the dividend yield is four-and-a-half percent on an annualized basis.
Underneath the deal arithmetic, the second-quarter operating print was in line, not exciting, and not the kind of quarter a board would willingly walk away from a strategic process over. Net sales of $3,955M were up 3.0% as reported. Organic growth was 1.6%. Skin Health and Beauty carried the quarter with a 5.1% reported print, while Self Care and Essential Health were both in the low single digits. Reported gross margin of 58.2% slipped seventy basis points as tariffs and input inflation offset supply-chain savings. Operating income still edged up 1.0%. Net income rose 8.6% helped by a tax-rate drop of nearly five hundred basis points. The half-year view looks firmer, with operating income growth running well ahead of revenue.
The investment question is therefore a deal-versus-stand-alone exercise, and the relevant variables for the next three months are tightly defined. Three things determine the outcome: whether the foreign regulatory clearances arrive on the timeline embedded in the merger agreement, whether the combined entity can deliver the cost synergies the deal narrative implies once the two supply chains integrate, and whether the stand-alone business can keep organic growth in the low single digits while gross margin recovers from the second-quarter tariff pressure. The bull case is that the deal closes on schedule, the cash-plus-stock mix captures most of the deal value at the implied per-share price, and the dividend continues to compound. The bear case is that foreign regulators extract concessions that delay the close into 2027, the stand-alone business decelerates, or the Kimberly-Clark share price falls and pulls the implied deal value down with it. The single most important forward variable to monitor is the regulatory clearance calendar; the second is the third-quarter organic growth print; the third is Kimberly-Clark's own share-price trajectory.